Adma Biologics (ADMA) Gross Profit (2011 - 2025)

Adma Biologics has reported Gross Profit for 13 years, with the latest figure at $88.8 million in Q4 2025.

• For the quarter ending Q4 2025, Gross Profit rose 40.24% year-over-year to $88.8 million; the trailing twelve-month figure through Dec 2025 stood at $292.8 million (up 33.35% YoY), and the FY2025 full-year result was $292.8 million, up 33.35% from the prior year.
• Gross Profit for Q4 2025 stood at $88.8 million, up from $75.6 million in the prior quarter.
• The five-year high for Gross Profit was $88.8 million in Q4 2025, with the low at -$1.7 million in Q1 2021.
• Historically, Gross Profit has averaged $31.9 million across 5 years, with a median of $20.7 million in 2023.
• Annual changes were most pronounced in 2021 — Gross Profit sank 117.75% — and 2022, when it soared 2406.02%.
• Adma Biologics' Gross Profit stood at $3.5 million in 2021, then jumped by 303.76% to $14.2 million in 2022, then surged by 119.27% to $31.1 million in 2023, then surged by 103.73% to $63.3 million in 2024, then soared by 40.24% to $88.8 million in 2025.
• The last three Gross Profit figures came in at $88.8 million (Q4 2025), $75.6 million (Q3 2025), and $67.2 million (Q2 2025), per Business Quant data.